Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Carmot Therapeutics
Biotech
Roche’s GLP-1/GIP diabetes data fuel best-in-disease hopes
The phase 2 trial hit its primary endpoints, painting the asset as a potential treatment for people with type 2 diabetes and overweight or obesity.
Nick Paul Taylor
Sep 22, 2026 5:20am
Roche unveils strategy to become 'top 3' obesity company
Sep 22, 2025 8:05am
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Jul 24, 2025 5:00am
Roche hopes obesity drug will show 25% weight loss one day
Sep 11, 2024 11:45am
Roche’s $2.7B weight-loss wager delivers early oral GLP-1 win
Jul 17, 2024 6:00am
Top 10 smartest deals in biopharma
Jun 24, 2024 6:00am
